Early data show CAM360 effective for dry eye in 2 days
Click Here to Manage Email Alerts
NASHVILLE, Tenn. — BioTissue’s CAM360 AmnioGraft is showing early success in treating mild to moderate dry eye, according to a company executive here at Optometry’s Meeting.
“From early evaluations we’re seeing that mild to moderate dry eye disease seems to be a home run,” BioTissue director of marketing, Roger Kennedy, told Healio. “The new data show effectiveness in as early as 2 days.”
CAM360 AmnioGraft, a cryopreserved amniotic membrane (CAM) “ideal for patients who have mild to moderate dry eye disease and other ocular surface conditions,” is placed under a bandage contact lens, “increasing patient comfort and treatment efficacy while patients go on with their normal daily lives,” according to a company press release.
The ringless CAM “is shelf stable, but it is cryopreserved, which retains all the key biologics to help it be effective,” Kennedy said. “Being shelf stable has been an advantage; it’s more convenient for institutions that have more of a bureaucracy and in Northeast practices where real estate is at a premium.”
With the company’s progressive launch strategy, the product is currently available in 13 regions, he said.
“We’re working to identify a patient profile and relevant disease states and do that in a progressive, timely fashion,” he said. “We’re interviewing customers to see if they have five or six patients lined up to get a good subset to learn how they’re doing it, steps they’re taking, how long they’re going to be using it for.”
Kennedy said BioTissue anticipates full availability by the end of summer.
Collapse
Read more about
Click Here to Manage Email Alerts